Highlights Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Delayed Toronto S.E. Other stock markets 20:09:26 14/05/2024 BST			5-day change	1st Jan Change
2.97 ^CAD	-1.33%		+8.39%	+170.00%

05:31pm	Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure	MT
04-22	HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure	04:31pm	MT
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Cardiol Therapeutics Inc. Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx? for Recurrent Pericarditis	02-21	CI
Cardiol Therapeutics Receives Orphan Drug Designation From FDA for Lead Drug Candidate to Treat Pericarditis	02-15	MT
Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	01-09	CI
Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot	12-06	CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Cardiol Therapeutics Inc. Announces 50% Enrollment in Its Phase Ii Maveric-Pilot Study in Recurrent Pericarditis	11-01	CI
Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction	10/10/23	CI
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx? for the Treatment of Acute Myocarditis	19/09/23	CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in A Model of Heart Failure	07/03/23	CI
Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis	17/01/23	CI
Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis	12/12/22	CI
Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis	07/11/22	CI
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases	25/10/22	CI
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits	03/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Highlights

Filters